Gabelli Funds’s 4D Molecular Therapeutics FDMT Stock Holding History

Gabelli Funds’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,000	Closed	-$90K	–	1288
2025 Q4	$90K	Buy	+12,000	New	+$122K	﹤0.01%	1187

Other funds holding FDMT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Gabelli Funds's FDMT Position: Q1 2026 in Review

Gabelli Funds sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 12,000 shares — an estimated $90K sold.

Gabelli Funds first reported a position in FDMT in Q4 2025 and held it in 1 quarter. The position peaked at $90K in Q4 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

Gabelli Funds reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
Gabelli Funds sold 12,000 4D Molecular Therapeutics shares in Q1 2026, an estimated $90K.
Gabelli Funds first reported a position in 4D Molecular Therapeutics in Q4 2025 and held it in 1 quarter.
Gabelli Funds's 4D Molecular Therapeutics position peaked at $90K in Q4 2025.
152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Gabelli Funds's 13F filing for Q1 2026, filed 14 May 2026.